Lentigo maligna: Melanoma in situ on chronically sun-damaged skin

Archives of Pathology and Laboratory Medicine

Volumn 135, Issue 7, 2011, Pages 838-841

  Reed, Jon A ^a,b   Shea, Christopher R ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Cellnetix Pathology and Laboratories   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER STAGING; HUMAN; MALIGNANT LENTIGO; PATHOLOGY; REVIEW; SKIN; SKIN TUMOR; SUNLIGHT;

HUMANS; HUTCHINSON'S MELANOTIC FRECKLE; NEOPLASM STAGING; SKIN; SKIN NEOPLASMS; SUNLIGHT;

EID: 79960760896     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969;29(3):705-727.
2. McGovern VJ, Mihm MC Jr, Bailly C, et al. The classification of malignant melanoma and its histologic reporting. Cancer. 1973;32(6):1446-1457.
3. McGovern VJ, Cochran AJ, Van der Esch EP, Little JH, MacLennan R. The classification of malignant melanoma, its histological reporting and registration: a revision of the 1972 Sydney classification. Pathology. 1986; 18(1): 12-21. (Pubitemid 16118166)
4. Mihm MC Jr, Clark WH Jr, From L. The clinical diagnosis, classification and histogenetic concepts of the early stages of cutaneous malignant melanomas. N Engl J Med. 1971;284(19):1078-1082.
5. Clark WH Jr, Mihm MC Jr. Lentigo maligna and lentigo-maligna melanoma. Am J Pathol. 1969,55(1 ):39-67.
6. Finan MC, Perry HO. Lentigo maligna: a form of malignant melanoma in situ. Geriatrics. 1982;37(12):113-115.
7. NIH Consensus conference. Diagnosis and treatment of early melanoma. JAMA. 1992;268(10):1314-1319.
8. Mishima Y, Tanay A. The effect of alpha-methyldopa and ultraviolet irradiation on melanogenesis. Dermatologica. 1968; 136(2): 105-114.
9. Houghton AN, Viola MV. Solar radiation and malignant melanoma of the skin. J Am Acad Dermatol. 1981;5(4):477-483. (Pubitemid 12247100)
10. Cruber SB, Barnhill RL, Stenn KS, Roush GC. Nevomelanocytic proliferations in association with cutaneous malignant melanoma: a multivariate analysis. J Am Acad Dermatol. 1989,21(4, pt 1):773-780. (Pubitemid 19251742)
11. Elwood JM, Gallagher RP, Davison J, Hill GB. Sunburn, suntan and the risk of cutaneous malignant melanoma-The Western Canada Melanoma Study. Br J Cancer. 1985;51(4):543-549. (Pubitemid 15087093)
12. Holman CD, Armstrong BK. Cutaneous malignant melanoma and indicators of total accumulated exposure to the sun: an analysis separating histogenetic types. J Natl Cancer Inst. 1984;73(1):75-82. (Pubitemid 14090830)
13. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline pi 6 mutations in familial melanoma. Nat Genet. 1994;8(1):15-21.
14. Costello MJ, Fisher SB, Defeo CP. Melanotic freckle, lentigo maligna. Arch Dermatol. 1959;80:753-771.
15. Klauder JV, Beerman H. Melanotic freckle (Hutchinson), melanose circonscrite precancereuse (Dubreuilh). AMA Arch Derm. 1955;71(1):2-10.
16. McGovern VJ, Shaw HM, Milton GW, Farago GA. Is malignant melanoma arising in a Hutchinson's melanotic freckle a separate disease entity? Histopathology. 1980;4(3):235-242. (Pubitemid 10062979)
17. Mishima Y. Melanosis circumscripta praecancerosa (Dubreuilh), a nonnevoid premelanoma distinct from junction nevus. J Invest Dermatol. 1960;34: 361-375.
18. Prieto VG, McNutt NS, Prioleau PC, Shea CR. Scaly erythematous lesion in a patient with extensive solar damage: malignant melanoma in situ, amelanotic type. Arch Dermatol. 1996;132(10):1239-1242.
19. Borkovic SP, Schwartz RA. Amelanotic lentigo maligna melanoma manifesting as a dermatitislike plaque. Arch Dermatol. 1983;119(5):423-425. (Pubitemid 13135297)
20. Burket JM. Amelanotic lentigo maligna. Arch Dermatol. 1979,115(4):496. (Pubitemid 9178485)
21. Kelly RI, Cook MG, Mortimer PS. Aggressive amelanotic lentigo maligna. Br J Dermatol. 1994;131(4):562-565. (Pubitemid 24315428)
22. Paver K, Stewart M, Kossard S, Krivanek J. Amelanotic lentigo maligna. Austrahs J Dermatol. 1981;22(3):106-108. (Pubitemid 12078423)
23. Pichler E, Fritsch P. Macular amelanotic melanoma in situ. Dermatologica. 1988; 177(5):313-316.
24. Rahbari H, Nabai H, Mehregan AH, Mehregan DA, Mehregan DR, Lipinski J. Amelanotic lentigo maligna melanoma: a diagnostic conundrum- presentation of four new cases. Cancer. 1996;77(10):2052-2057.
25. Su WP, Bradley RR. Amelanotic lentigo maligna. Arch Dermatol. 1980; 116(1):82-83. (Pubitemid 10211857)
26. Tannous ZS, Lerner LH, Duncan LM, Mihm MC Jr, Flotte TJ. Progression to invasive melanoma from malignant melanoma in situ, lentigo maligna type. Hum Pathol. 2000;31(6):705-708. (Pubitemid 30445474)
27. Dubow BE, Ackerman AB. Ideas in pathology-malignant melanoma in situ: the evolution of a concept. Mod Pathol. 1990;3(6):734-744.
28. Katz SK, Guitart J. Starburst giant cells in benign nevomelanocytic lesions. J Am Acad Dermatol. 1998;38(2, pt 1):283. (Pubitemid 28100853)
29. Stevens C, Cockerell CJ. Avoiding sampling error in the biopsy of pigmented lesions. Arch Dermatol. 1996;132(11):1380-1382. (Pubitemid 26386632)
30. Duve S, Schmoeckel C, Burgdorf WH. Melanocyte hyperplasia in scars: a histopathological investigation of 722 cases. Am J Dermatopathol. 1996,18(3): 236-240. (Pubitemid 26230848)
31. Prieto VG, Argenyi ZB, Barnhill RL, et al. Are en face frozen sections accurate for diagnosing margin status in melanocyte lesions? Am J Clin Pathol. 2003;120(2):203-208. (Pubitemid 37046354)
32. Bhawan J. Mel-5: a novel antibody for differential diagnosis of epidermal pigmented lesions of the skin in paraffin-embedded sections. Melanoma Res. 1997;7(1):43-48. (Pubitemid 27110281)
33. Demartini CS, Dalton MS, Ferringer T, Elston DM. Melan-A/MART-1 positive "pseudonests" in lichenoid inflammatory lesions: an uncommon phenomenon. Ami Dermatopathol. 2005;27(4):370-371. (Pubitemid 41232500)
34. Helm K, Findeis-Hosey J. Immunohistochemistry of pigmented actinic keratoses, actinic keratoses, melanomas in situ and solar lentigines with Melan-A. ; Cutan Pathol. 2008;35(10):931-934.
35. Kelley LC, Starkus L. Immunohistochemical staining of lentigo maligna during Mohs micrographic surgery using MART-1. J Am Acad Dermatol. 2002; 46(1):78-84. (Pubitemid 34073482)
36. Lane H, O'Loughlin S, Powell F, Magee H, Dervan PA. A quantitative immunohistochemical evaluation of lentigo maligna and pigmented solar keratosis. Am J Clin Pathol. 1993;100(6):681-685. (Pubitemid 24004126)
37. Menaker GM, Chiang JK, Tabila B, Moy RL. Rapid HMB-45 staining in Mohs micrographic surgery for melanoma in situ and invasive melanoma. J Am Acad Dermatol. 2001;44(5):833-836. (Pubitemid 32391173)
38. Kamb A, Shattuck-Eidens D, Eeles R, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet. 1994;8(1):23-26.
39. Reed JA, Loganzo FJ, Shea CR, et al. Loss of expression of the p16/cyclindependent kinase inhibitor 2 tumor suppressor gene in melanocyte lesions correlates with invasive stage of tumor progression. Cancer Res. 1995,55(13): 2713-2718.
40. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954. (Pubitemid 34716871)
41. Lang J, MacKie RM. Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes. J Invest Dermatol. 2005;125(3):575-579.
42. Saldanha G, Potter L, Daforno P, Pringle JH. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies. Clin Cancer Res. 2006;12(15):4499-4505. (Pubitemid 44297798)
43. Bastian BC, Olshen AB, LeBoit PE, Pinkel D. Classifying melanocyte tumors based on DNA copy number changes. Am J Pathol. 2003;163(5):1765-1770. (Pubitemid 37310008)
44. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl 1 Med. 2005;353(20):2135-2147. (Pubitemid 41653105)
45. Gerami P, Mafee M, Lurtsbarapa T, Guitart J, Haghighat Z, Newman M. Sensitivity of fluorescence in situ hybridization for melanoma diagnosis using RREB1, MYB, Cep6, and 11 ql 3 probes in melanoma subtypes. Arch Dermatol. 2010;146(3):273-278.
46. Grammatico P, Modesti A, Steindl K, et al. Lentigo maligna: cytogenetic, ultrastructural, and phenotypic characterization of a primary cell culture. Cancer Genet Cytogenet. 1992;60(2):141-146.
47. Plummer RS, Shea CR, Nelson M, et al. PAX3 expression in primary melanomas and nevi. Mod Pathol. 2008;21(5):525-530. (Pubitemid 351589648)
48. Reed JA, Bales E, Xu W, Okan NA, Bandyopadhyay D, Medrano EE. Cytoplasmic localization of the oncogenic protein Ski in human cutaneous melanomas in vivo: functional implications for transforming growth factor beta signaling. Cancer Res. 2001;61(22):8074-8078. (Pubitemid 33091592)
49. Reed JA, Lin Q, Chen D, Mian IS, Medrano EE. SKI pathways inducing progression of human melanoma. Cancer Metastasis Rev. 2005;24(2):265-272. (Pubitemid 40922798)
50. Reed JA. Deciphering the melanoma interactome. J Cutan Pathol. 2008; 35(suppl 2):11-15.
51. Erickson C, Miller SJ. Treatment options in melanoma in situ: topical and radiation therapy, excision and Mohs surgery. Int J Dermatol. 2010;49(5):482-491.
52. McKenna JK, Florell SR, Goldman GD, Bowen GM. Lentigo maligna/lentigo maligna melanoma: current state of diagnosis and treatment. Dermatol Surg. 2006;32(4):493-504.